Visual cortex of the brain develops gradually throughout life, study reveals

A study of post-mortem brain tissue reveals the human primary visual cortex (V1) develops gradually throughout life. The research, published in The Journal of Neuroscience, may help to explain why the structure of this part of the brain matures in the first years after birth while vision continues to change throughout the lifespan.

Kathryn Murphy and colleagues obtained brain samples from 30 deceased individuals ranging from birth to 80 years of age to study how expression of a set of glutamatergic proteins (which regulate neurotransmission at a majority of synapses in human V1) changes in this region over time. The results show development of human V1 occurs in five different stages that mirror changes in vision. For example, the expression of three of these proteins peaks between 5 and 11 years of age, which coincides with the end of the period when children are susceptible to developing amblyopia, or lazy eye. Another protein did not peak until about 40 years of age and then dropped dramatically, by about 75 percent, in adults over 55 years of age, perhaps signaling degeneration in human V1.

The authors conclude that their work may inform the development of vision therapies for individuals of different ages.​​

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial